Physician

Shilpa Sambidi, M.D.

According to 2025 Medicare claims, Shilpa Sambidi, M.D. (NPI: 1821240011) practices hematology/oncology in the Binghamton, NY market, with the plurality of this provider's patient population coming from Broome, NY. This provider's primary affiliated billing organization is BROOME ONCOLOGY LLC (NPI: 1518956176; TIN: 16-1611703) and primary practice location at 13905-4246.

Sambidi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 669 traditional Medicare patients, billed 163,763 HCPCS/CPT codes, and received $2,086,503 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,016 prescription claims across 314 beneficiaries totaling $2,953,708 in drug costs, led by Lenalidomide (Lenalidomide). 2022 DME data shows 12 claims. Open Payments data shows 77 records totaling $1,328. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,109,070 to $2,086,503. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,127,196 to $2,953,708. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	613	86,659	$1,109,070
2016	727	127,956	$1,519,600
2017	739	159,567	$1,932,563
2018	745	145,185	$2,004,872
2019	715	134,100	$1,785,789
2020	670	89,740	$1,534,986
2021	659	102,396	$1,656,593
2022	643	121,129	$2,016,965
2023	679	164,208	$2,103,703
2024	669	163,763	$2,086,503

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	172	705	$1,127,196
2016	203	809	$1,007,627
2017	181	731	$1,279,728
2018	178	705	$1,208,015
2019	163	591	$991,032
2020	197	557	$1,445,480
2021	200	645	$2,025,740
2022	218	682	$1,677,414
2023	276	953	$2,795,618
2024	314	1,016	$2,953,708

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	40	$3,368
2016	N/R	26	$1,380
2017	N/R	42	$10,654
2018	N/R	37	$3,574
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	12	$690
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	315	733	$99
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	318	438	$63
80053	Blood test, comprehensive group of blood chemicals	389	960	$10
36415	Insertion of needle into vein for collection of blood sample	451	1,194	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	435	1,116	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	25	682	$353,129
Revlimid	Lenalidomide	20	560	$340,208
Cabometyx	Cabozantinib S-Malate	13	390	$327,742
Jakafi	Ruxolitinib Phosphate	12	360	$194,314
Imbruvica	Ibrutinib	13	374	$189,554

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	77	$1,328	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Shilpa Sambidi, M.D.?

Tedicare shows public-source Medicare data for Shilpa Sambidi, M.D. (NPI 1821240011), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Shilpa Sambidi, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Shilpa Sambidi, M.D.?

Shilpa Sambidi, M.D. is linked to BROOME ONCOLOGY LLC (billing NPI 1518956176) in the available physician profile data.

Does Shilpa Sambidi, M.D. have Open Payments data?

Shilpa Sambidi, M.D. has 77 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.